Safety and efficacy of tofacitinib in 97 alopecia areata patients
Journal of Cosmetic Dermatology · 2024-09 · 23 (9) · 2807-2813
DOI: 10.1111/jocd.16356 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 12.05.2024. Verfasst von Maryam Nasimi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology, Dermatology Department, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, Alopecia Areata, Protein Kinase Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Alopecia areata (AA) is a recurrent immune‐mediated disorder causing hair loss without any scarring being present. It affects hairs on the head or other parts of the body and can occur at any age and in both genders. It seems that AA is associated with a higher rate of psychological disorders resulting from hair loss and the esthetic and social repercussions of it. Common treatments like corticosteroids do not work for every patient and recent treatment options focusing on the immunologic mechanisms like tofacitinib have shown some promising results.
Methods
It's a retrospective study on patients with AA, AT, AU taking oral tofacitinib as a treatment for at least 6 months. Scalp hair loss was assessed before treatment and at each visit using the Severity of Alopecia Tool (SALT) score.
Results
Of 97 cases, 69.1% demonstrated over 50% SALT score improvement, with 44.3% having 90% or more decrease in SALT score. Patients who suffered from patchy AA were more responsive compared to patients with AT and AU subtypes and had a greater percent change in SALT score. Tofacitinib was tolerated quite well and no significant adverse events were reported.
Conclusions
Tofacitinib should be taken into consideration as an efficacious treatment option for patients with AA, AT and AU.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology, Dermatology Department, Tehran University of Medical Sciences, Tehran, Iran.
- Statistics, Blood transfusion Research Center, High Institute for Research and Education, Tehran, Iran.
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Maryam Nasimi, Hanie Babaie
Zitieren
APA
Nasimi, M., Abedini, R., Ghandi, N., Teymourpour, A., & Babaie, H. (2024). Safety and efficacy of tofacitinib in 97 alopecia areata patients. Journal of Cosmetic Dermatology, 23(9), 2807-2813. https://doi.org/10.1111/jocd.16356
Vancouver
Nasimi M, Abedini R, Ghandi N, Teymourpour A, Babaie H. Safety and efficacy of tofacitinib in 97 alopecia areata patients. Journal of Cosmetic Dermatology. 2024;23(9):2807-2813. doi:10.1111/jocd.16356
BibTeX
@article{Nasimi2024,
author = {Nasimi, Maryam and Abedini, Robabeh and Ghandi, Narges and Teymourpour, Amir and Babaie, Hanie},
title = {Safety and efficacy of tofacitinib in 97 alopecia areata patients},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
volume = {23},
number = {9},
pages = {2807--2813},
doi = {10.1111/jocd.16356}
}
EUVIMED